← Back to Clinical Trials
Recruiting NCT07694063

NCT07694063 Online Hatha Yoga Program as an Add-On Therapy for Episodic High-Frequency Migraine

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07694063
Status Recruiting
Phase
Sponsor University of Seville
Condition Migraine
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2026-01-27
Primary Completion 2026-10-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Control group (receiving standard medical therapy alone)Hatha yoga

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2026-01-27 with a primary completion date of 2026-10-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled trial aims to evaluate the effectiveness and feasibility of an online Hatha yoga program as an adjunct (add-on) therapy for patients with high-frequency episodic migraine. Participants will be randomly assigned to either an intervention group receiving a 12-week home-based online Hatha yoga program in addition to usual pharmacological treatment, or a control group receiving usual pharmacological care only. Outcomes include migraine frequency, pain intensity, functional disability, sleep quality, psychological symptoms, and adherence.

Eligibility Criteria

Inclusion Criteria * Adults aged 18-65 years * Diagnosis of episodic high-frequency migraine according to ICHD criteria * Diagnosis confirmed by a neurologist * At least 1-year history of migraine * Receiving stable pharmacological treatment for ≥3 months before enrollment * Willing to maintain stable medication during the study * Ability to understand study procedures and complete assessments * Signed informed consent * Willingness to be randomized Exclusion Criteria * Other significant neurological disorders * Severe psychiatric conditions affecting participation * Medical contraindications to moderate physical activity * Chronic migraine (≥15 headache days/month) * Use of more than one preventive migraine medication * Lack of Spanish language comprehension * Lack of internet access or digital skills for online intervention

Contact & Investigator

Central Contact

Cristina García Muñoz, PhD, PT

✉ ccriss.g@gmail.com

📞 +34954551468

Principal Investigator

Cristina García Muñoz, PhD

PRINCIPAL INVESTIGATOR

University of Seville

Frequently Asked Questions

Who can join the NCT07694063 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07694063 currently recruiting?

Yes, NCT07694063 is actively recruiting participants. Contact the research team at ccriss.g@gmail.com for enrollment information.

Where is the NCT07694063 trial being conducted?

This trial is being conducted at Seville, Spain.

Who is sponsoring the NCT07694063 clinical trial?

NCT07694063 is sponsored by University of Seville. The principal investigator is Cristina García Muñoz, PhD at University of Seville. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology